PDL BioPharma Announces First Quarter 2017 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- Wall St rises on cooler inflation data, big bank earnings
- IBM plunges 19% as memory capex squeeze derails Q2 earnings
- SK Hynix’s record plunge drags down global chip stocks
- Software stocks tumble: High memory prices cannibalize enterprise tech capex
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- IBM misses Q2 targets as mainframe and software sales disappoint
- Goldman Sachs Upgrades NIO (NIO) to Buy
- BofA Securities on AppLovin: 'Current valuation appears reasonable'
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- YPF Energía Eléctrica S.A. files for proposed NYSE IPO
PDL BioPharma (PDLI) Posts Q1 EPS of $0.04
May 3, 2017 4:56 PM EDTPDL BioPharma (NASDAQ: PDLI) reported Q1 GAAP EPS of $0.04, which may not compare to the analyst estimate of $0.05. Revenue for the quarter came in at $45.4 million versus the consensus estimate of $50.23 million.
For earnings history and earnings-related data on PDL BioPharma (PDLI) click here.
... More